The agreement, which covers Interpace's ThyGenX and ThyraMIR diagnostic tests for the diagnosis of thyroid cancer in patients with indeterminate thyroid nodules.
During the quarter, the firm secured payor coverage for its tests with UnitedHealthcare, Premera Blue Cross, and Aetna.
Among its business highlights for the quarter, the firm established coverage for the Afirma genomic sequencing classifier by all major insurance plans.
Interpace Diagnostics said that the test will now be covered for Cigna's roughly 15 million members nationwide.
The team showed in a study this week that they could detect BRAF mutations in thyroid cancer, and believe the method could also allow blood-based early cancer detection.
Using a combination of genome-wide association and expression quantitative trait loci approaches, investigators uncovered shared and population-specific thyroid cancer risk loci.
The test is now covered by Premera Blue Cross, a regional health plan with more than 2 million members located primarily in Washington, Oregon, and Alaska.
The New York State Department of Health had previously provided conditional approval of the microRNA classifier for diagnosing indeterminate thyroid cancer cases.
The company missed analyst estimates on the top line, but beat expectations for loss per share during the quarter.
After a 54 percent quarter over quarter rise in sales of the test, Rosetta's CEO said that the realigned strategy will take the firm to profit more quickly.
Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.
The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.
In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.
Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.